Dabrafenib and trametinib-induced hyperglycemia with decreased insulin secretion in a patient with lung adenocarcinoma
Abstract
Hyperglycemia is an adverse effect of targeted cancer therapies; however, the mechanisms underlying B-Raf proto-oncogene, serine/threonine kinase (BRAF)/mitogen-activated protein kinase kinase (MEK) inhibitor-associated hyperglycemia remain unclear. We describe an 80-year-old man who developed severe hyperglycemia during combination therapy with dabrafenib and trametinib for BRAF V600E-positive lung adenocarcinoma. Before treatment, he was obese and had unrecognized mild diabetes. Seven months after treatment initiation, he presented with hyperglycemia accompanied by a reduced insulin secretory capacity. Serial measurements of the C-peptide index revealed that the temporary withdrawal of dabrafenib-trametinib resulted in the recovery of insulin secretion, which gradually decreased again upon reinitiation. This case underscores the clinical importance of monitoring both the glycemic status and insulin secretion in patients receiving BRAF/MEK inhibitors.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.